Genelux (NASDAQ:GNLX) CEO Sells $42,201.09 in Stock

Genelux Corporation (NASDAQ:GNLX) CEO Thomas Zindrick sold 12,673 shares of the company’s stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $3.33, for a total value of $42,201.09. Following the sale, the chief executive officer owned 542,940 shares in the company, valued at approximately $1,807,990.20. This trade represents a 2.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Thomas Zindrick also recently made the following trade(s):

• On Monday, November 17th, Thomas Zindrick sold 4,509 shares of Genelux stock. The stock was sold at an average price of $5.37, for a total value of $24,213.33.

Genelux Trading Down 2.4%

NASDAQ:GNLX traded down $0.11 during midday trading on Thursday, hitting $4.40. 77,387 shares of the company traded hands, compared to its average volume of 191,698. The firm has a market capitalization of $167.42 million, a P/E ratio of -5.00 and a beta of 0.06. The firm’s fifty day moving average is $5.74 and its 200-day moving average is $4.17. Genelux Corporation has a 12-month low of $1.99 and a 12-month high of $8.53.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. On average, research analysts expect that Genelux Corporation will post -0.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GNLX has been the topic of several analyst reports. Loop Capital set a $16.00 price target on shares of Genelux in a report on Tuesday, October 21st. Lake Street Capital started coverage on Genelux in a research note on Tuesday, October 21st. They set a “buy” rating and a $16.00 target price on the stock. Maxim Group set a $20.00 price target on Genelux in a report on Tuesday, October 21st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Institutional Trading of Genelux

Large investors have recently modified their holdings of the company. Private Management Group Inc. bought a new position in Genelux in the second quarter worth approximately $33,000. American Century Companies Inc. bought a new stake in Genelux during the 1st quarter valued at $51,000. Beacon Capital Management LLC lifted its holdings in shares of Genelux by 99.8% in the 2nd quarter. Beacon Capital Management LLC now owns 19,116 shares of the company’s stock worth $55,000 after buying an additional 9,550 shares during the period. Falcon Wealth Planning grew its position in shares of Genelux by 83.3% during the 2nd quarter. Falcon Wealth Planning now owns 22,000 shares of the company’s stock worth $63,000 after buying an additional 10,000 shares in the last quarter. Finally, 5T Wealth LLC grew its position in shares of Genelux by 33.9% during the 3rd quarter. 5T Wealth LLC now owns 24,101 shares of the company’s stock worth $101,000 after buying an additional 6,100 shares in the last quarter. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.